EG427

EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy.

Our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. Our research capability is focussed on ensuring our powerful platform approach has wide applicability, with potential for many products across several therapeutic areas with severe unmet medical needs.

Our first targets in the peripheral nervous system are Type C sensory neurons. Our lead asset, EG110A, targeting these neurons, is in preclinical development for the treatment of neurogenic bladder dysfunction, also called NDO. It is expected to be in the clinic by early 2024. Our revolutionary approach to the treatment of NDO aims to provide patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular surgery approach overcoming the significant drawbacks of the current standard of care.